MDL 2921 Allergan Breast Implant Case Management Orders
Below are links to each case management order in MDL 2921 for the Allergan Biocell breast implant lawsuits. MDL 2921 has been in existence since December 2019 and there are now numerous case management orders on file. Staying current with the Allergan breast implant case management orders is a good way to stay up to date on the status of MDL 2921. Bookmark this page, as Allergan breast implant case management orders are added once they have been entered on the docket for MDL 2921.
01/07/2020: Initial Case Management Order – Setting Initial Conference [PDF]
01/13/2020: Case Management Order No. 2 – Initial Conference Summary, 2020 Conference Schedule & Leadership Directives [PDF]
02/10/2020: Case Management Order No. 3 – February CMC Summary, Preemption Briefing & Anonymous Plaintiff Identification [PDF]
02/25/2020: Case Management Order No. 4 – Appointment of Plaintiffs’ Leadership Counsel & Steering Committee [PDF]
3/16/2020: Case Management Order No. 5 – March CMC Summary, Oral Argument Scheduling & Procedural Directives [PDF]
08/19/2020: Amended Case Management Order No. 6 – Direct Filing Procedures & Presumptive Place of Remand [PDF]
05/06/2020: Amended Case Management Order No. 7 – Streamlined Service of Process via Email for Allergan Defendants [PDF]
3/23/2020: Case Management Order No. 8 – Service of Fact Sheets & Medical Authorizations through MDL Centrality [PDF]
04/20/2020: Case Management Order No. 9 – April CMC Summary, Master Complaint Deadlines & Discovery Stay [PDF]
05/19/2020: Case Management Order No. 10 – May CMC Summary, Master Complaint & Rule 12(b)(6) Briefing Deadlines [PDF]
05/22/2020: Case Management Order No. 11 – Science Day Ground Rules & Educational Presentation Schedule [PDF]
09/23/2020: Second Amended Case Management Order No. 12 – Comprehensive Protective Order & Confidentiality Protocols [PDF]
07/15/2020: Case Management Order No. 13 – July CMC Summary, Master Complaint Implementation & Motion to Dismiss Scheduling [PDF]
08/19/2020: Case Management Order No. 14 – August CMC Summary, Short Form Complaint Directives & 2021 Planning [PDF]
09/14/2020: Case Management Order No. 16 – September CMC Summary, Proper Parties Order & Revised Pleading Deadlines [PDF]
09/15/2020: Case Management Order No. 17 – Master Long Form and Short Form Complaint Implementation & Multi-Plaintiff Severance [PDF]
09/15/2020: Case Management Order No. 18 – Proper Party Defendant Stipulation & Dismissal of Related Entities [PDF]
11/13/2020: Case Management Order No. 19 – Oral Argument Scheduling & Time Limits for Motions to Dismiss [PDF]
12/15/2020: Case Management Order No. 20 – Supplemental Briefing Directives & Discovery Coordination [PDF]
04/30/2021: Case Management Order No. 22 – Judicial Assignment of Magistrate Judge Kiel, Appointment of Special Master & Motion to Dismiss Ruling [PDF]
06/23/2021: Case Management Order No. 23 – Deadlines and Procedures for Defendants’ Master Answers [PDF]
08/01/2022: Case Management Order No. 25 – Modification of Appointments to the Plaintiffs’ Steering Committee [PDF]
10/02/2023: Case Management Order No. 26 – Bellwether Selection Deadlines, Discovery Updates & Class Action Briefing Schedule [PDF]
10/05/2023: Case Management Order No. 27 – Modification of Appointments to the Plaintiffs’ Steering Committee [PDF]
02/09/2024: Case Management Order No. 28 – Bellwether Selection Deadlines & Core Discovery Schedule [PDF]
05/13/2024: Case Management Order No. 29 – 2024 Case Management Conference Schedule & Dial-In Procedures [PDF]
05/16/2024: Case Management Order No. 30 – Extension of Bellwether Selection and Core Discovery Deadlines [PDF]
01/08/2025: Amended Case Management Order No. 31 – 2025 Case Management Conference Schedule & Remote Procedures [PDF]
09/04/2024: Special Master Case Management Order No. 32 – Ruling on Document Retention and Litigation Hold Discovery [PDF]
05/19/2025: Case Management Order No. 33 – Modification of Appointments to the Plaintiffs’ Steering Committee [PDF]
06/25/2025: Case Management Order No. 34 – Explant Trial Bellwether Selection, Pretrial Discovery Deadlines & Mediation Schedule [PDF]
09/10/2025: Case Management Order No. 35 – 2026 Case Management Conference Schedule & Dial-In Procedures [PDF]
10/07/2025: Case Management Order No. 36 – Discovery Protocols for Product-In-Place Plaintiffs & Random Sampling Guidelines [PDF]
10/14/2025: Case Management Order No. 37 – Refined 2026 Bellwether Trial Schedule & Pretrial Deadlines for Explant Cases [PDF]
12/24/2025: Case Management Order No. 38 – Establishment of QSF and Appointment of Administrators [PDF]
Allergan Breast Implant Lawsuit MDL 2921 Information
For more information on the status of MDL 2921, check out our page on the Breast Implant Lawsuit. For more information on the recall and specific symptoms, see the details below.
Why is the FDA recalling the Allergan Biocell breast implants?
The Food and Drug Administration (FDA) has issued a recall for all textured saline-filled breast implants manufactured by Allergan, Inc. The recall comes after reports of a rare cancer called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). In addition to the textured saline-filled breast implants, Allergan has also recalled one of their textured silicone gel filled breast implants.
What is BIA-ALCL?
BIA-ALCL is a rare form of lymphoma that develops around breast implants after they are placed. The lymphoma is an aggressive type of cancer that can spread quickly throughout the body and become life threatening if left untreated. In some cases, patients who develop BIA-ALCL may require chemotherapy or radiation therapy to treat the disease.
Signs & Symptoms of BIA-ALCL
This form of ALCL often begins with symptoms similar to those of other lymphomas, including:
Painless swelling in one or both breasts
Swelling around the neck or underarm area (lymph nodes)
Fever and night sweats (persistent high temperature)
Loss of appetite or weight loss
How is BIA-ALCL Diagnosed?
The FDA has recommended that women with textured breast implants undergo a CT scan of the chest and abdomen. This is because it can be difficult to distinguish between BIA-ALCL and other forms of lymphoma, such as SLL/CLL or FL. A biopsy of one or more lesions may also be performed in order to confirm the diagnosis.
For a free consultation with our breast implant attorneys, please call 202-792-7927.

Question

MDL 2921 Allergan Breast Implant Case Management Orders

Below are links to each case management order in MDL 2921 for the Allergan Biocell breast implant lawsuits. MDL 2921 has been in existence since December 2019 and there are now numerous case management orders on file. Staying current with the Allergan breast implant case management orders is a good way to stay up to date on the status of MDL 2921. Bookmark this page, as Allergan breast implant case management orders are added once they have been entered on the docket for MDL 2921.

Allergan Breast Implant Lawsuit MDL 2921 Information

For more information on the status of MDL 2921, check out our page on the Breast Implant Lawsuit. For more information on the recall and specific symptoms, see the details below.

Why is the FDA recalling the Allergan Biocell breast implants?

The Food and Drug Administration (FDA) has issued a recall for all textured saline-filled breast implants manufactured by Allergan, Inc. The recall comes after reports of a rare cancer called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). In addition to the textured saline-filled breast implants, Allergan has also recalled one of their textured silicone gel filled breast implants.

What is BIA-ALCL?

BIA-ALCL is a rare form of lymphoma that develops around breast implants after they are placed. The lymphoma is an aggressive type of cancer that can spread quickly throughout the body and become life threatening if left untreated. In some cases, patients who develop BIA-ALCL may require chemotherapy or radiation therapy to treat the disease.

Signs & Symptoms of BIA-ALCL

This form of ALCL often begins with symptoms similar to those of other lymphomas, including:

Painless swelling in one or both breasts
Swelling around the neck or underarm area (lymph nodes)
Fever and night sweats (persistent high temperature)
Loss of appetite or weight loss

How is BIA-ALCL Diagnosed?

The FDA has recommended that women with textured breast implants undergo a CT scan of the chest and abdomen. This is because it can be difficult to distinguish between BIA-ALCL and other forms of lymphoma, such as SLL/CLL or FL. A biopsy of one or more lesions may also be performed in order to confirm the diagnosis.

For a free consultation with our breast implant attorneys, please call 202-792-7927.

Accepted Answer